|Articles|August 4, 2016
New CEO for Inspyr Therapeutics
August 04, 2016
Advertisement
Inspyr Therapeutics, Inc. (San Antonio, TX) has appointed Christopher Lowe as President and Chief Executive Officer, and as a member of the Company’s Board of Directors. Mr. Lowe brings more than 15 years of executive management experience in life sciences as CEO, Chief Financial Officer and Chief Business Officer, and has been an advisor to the Inspyr’s Board of Directors since March 2016.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
2
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
3
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
4
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement
5